Format

Send to

Choose Destination
Expert Rev Endocrinol Metab. 2018 Jan;13(1):25-33. doi: 10.1080/17446651.2018.1411798. Epub 2017 Dec 7.

Medical versus surgical treatment of prolactinomas: an analysis of treatment outcomes.

Author information

1
a California Center for Pituitary Disorders, Department of Neurological Surgery , University of California , San Francisco , CA , USA.

Abstract

Prolactinomas are unique tumors that may go into both hormonal and radiographic remission with dopamine agonist therapy or transsphenoidal surgery. Regardless of modality, the goals of therapy remain the same: (1) biochemical remission, including reduction of prolactin and normalization of sex hormones; (2) radiographic tumor control, with a range including prevention of tumor growth, tumor regression, or complete tumor resolution; (3) resolution of preoperative symptoms, including those that are hormonal or neurologic; and (4) prevention of new hypopituitarism or new neurologic symptoms. Areas covered: In the following review, we performed a search of the literature using keywords 'prolactinoma,' 'dopamine agonist,' 'surgery,' 'cost-effectiveness,' 'recurrence,' and 'complication' to compare the relative merits of medical versus surgical therapy for prolactinoma, including special circumstances such as cystic tumors, pregnant patients, and the cost-effectiveness of different strategies. Expert commentary: Medical therapy can offer a cure, but surgery provides an important adjunct to patients with resistance or intolerance to dopamine agonists, and offers excellent outcomes including when combined with continued postoperative medical therapy. Further head to head comparisons will benefit patients and practitioners weighing the relative risks and benefits of medical and surgical intervention, including the issue of their relative cost-effectiveness.

KEYWORDS:

Prolactinoma; adenoma; dopamine agonist; pituitary; surgery

Supplemental Content

Loading ...
Support Center